GlaxoSmithKline, Progentec to Use AI and Wearables for Lupus Treatment

Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus (SLE or lupus). At least 5 million people worldwide are living with lupus, one of the most complex autoimmune diseases. It's difficult to diagnose and even more challenging to treat. The condition is associated with a range of debilitating symptoms that can fluctuate over time, including painful or swollen joints, extreme fatigue, unexplained fever, skin rashes, and organ damage. Up to 50% of SLE patients experience irreversible organ damage within five years of diagnosis and this damage is associated with a poor long-term prognosis and early mortality.